These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1948825)

  • 1. Anticoagulant and antithrombotic effects of combinations of defibrotide with heparins and other antithrombotic agents in an animal thrombosis model.
    Giedrojc J; Breddin HK
    Thromb Res; 1991 Jul; 63(1):99-110. PubMed ID: 1948825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of combinations of a prostacyclin analogue (Cicaprost) with different antithrombotic agents in a rat microcirculatory thrombosis model.
    Giedrojc J; Breddin HK
    Int J Microcirc Clin Exp; 1992 Aug; 11(3):277-86. PubMed ID: 1324230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model.
    Krupinski K; Breddin HK
    Haemostasis; 1991; 21 Suppl 1():88-92. PubMed ID: 1894199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antithrombotic effects of molsidomine alone and in combination with other antithrombotic agents in a thrombosis model of the microcirculation of the rat].
    Giedrojc J; Weichert W; Breddin HK
    Z Kardiol; 1991; 80 Suppl 5():35-9. PubMed ID: 1663678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of combinations of a molsidomin with different antithrombotic drugs in laser-induced thrombosis.
    Giedrojć J; Bielawiec M; Jaromin J; Breddin HK
    Mater Med Pol; 1993; 25(3-4):153-7. PubMed ID: 8072321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant and antithrombotic effects of chemically modified heparins and pentosanpolysulfate.
    Krupinski K; Breddin HK; Casu B
    Haemostasis; 1990; 20(2):81-92. PubMed ID: 1693353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered.
    Hiebert LM
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):264-272. PubMed ID: 27653610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antithrombotic properties of heparin independent of its anticoagulant activity].
    Krupiński K; Bielawiec M; Breddin HK
    Acta Haematol Pol; 1994; 25(3):243-51. PubMed ID: 7992597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual and combined effects of a thromboxane receptor antagonist and different antithrombotic agents in a rat microcirculatory thrombosis model.
    Giedrojc J; Fellier H; Breddin HK
    Haemostasis; 1992; 22(6):322-9. PubMed ID: 1335951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study on the in vitro and in vivo activities of heparinoids derivative investigated on the animal model.
    Giedrojć J; Klimiuk M; Radziwon P; Kłoczko J; Bielawiec M; Breddin HK
    J Cardiovasc Pharmacol; 1999 Sep; 34(3):340-5. PubMed ID: 10470990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic effect of OP/LMWH by subcutaneous route in rats.
    Fantuz M; Milani R; Andriuoli G; Mastacchi R; Barbanti M
    Arch Int Pharmacodyn Ther; 1986 Aug; 282(2):328-34. PubMed ID: 3767531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic and thrombolytic activity of heparins in a rat model of laser-induced thrombosis.
    Krupiński K; Giedrojć J; Breddin HK; Bielawiec M
    Pol J Pharmacol; 1996; 48(3):345-50. PubMed ID: 9112675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defibrotide affects the anticoagulant and lipase-releasing activities of heparin.
    Porta R; Pescador R; Mantovani M; Prino G
    Haemostasis; 1990; 20(6):347-56. PubMed ID: 2099323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model.
    Jing BB; Li YX; Zhang H; Ren ST; Wang M; Li YP; Zang WJ; Wang B
    Thromb Res; 2011 Nov; 128(5):463-9. PubMed ID: 21924458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolytic effects of defibrotide in atherosclerotic patients.
    Patrassi GM; Sartori MT; Viero ML; Scapinello MP; Boeri G; Girolami A
    Semin Thromb Hemost; 1991; 17 Suppl 1():101-5. PubMed ID: 2068562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat.
    Daykin HJ; Sturgeon SA; Jones C; Wright CE
    Thromb Res; 2006; 118(6):755-62. PubMed ID: 16410020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between the sulfated lactobionic acid (LW 10082) and other antithrombotic agents in animal thrombosis model.
    Giedrojć J; Krupiński K; Breddin HK; Bielawiec M
    Pol J Pharmacol; 1996; 48(3):317-22. PubMed ID: 9112669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical studies on a low molecular weight heparin.
    Fareed J; Jeske W; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A
    Thromb Res; 1996; 81(2 Suppl):S1-27. PubMed ID: 8822124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic and bleeding effects of a low molecular weight heparin fraction.
    Pangrazzi J; Abbadini M; Zametta M; Naggi A; Torri G; Casu B; Donati MB
    Biochem Pharmacol; 1985 Sep; 34(18):3305-8. PubMed ID: 4038339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological studies on the low molecular weight heparin derivative CY 216.
    Kaiser B; Kühnemuth G; Markwardt F
    Pharmazie; 1990 Jul; 45(7):522-4. PubMed ID: 2173004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.